Breaking News Instant updates and real-time market news.

BIIB

Biogen

$223.57

3.52 (1.60%)

06:44
10/22/19
10/22
06:44
10/22/19
06:44

Biogen soars 20% on plans to pursue Alzheimer's approval after FDA talks

Shares of Biogen are soaring after the company announced that, after consulting with the FDA, it plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease. "The decision to file is based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis. This new analysis of a larger dataset that includes additional data that became available after the pre-specified futility analysis shows that aducanumab is pharmacologically and clinically active as determined by dose-dependent effects in reducing brain amyloid and in reducing clinical decline as assessed by the pre-specified primary endpoint Clinical Dementia Rating-Sum of Boxes (CDR-SB). In both studies, the safety and tolerability profile of aducanumab was consistent with prior studies of aducanumab," The company plans to file a Biologics License Application in early 2020 and will continue dialogue with regulatory authorities in international markets including Europe and Japan. Shares of Biogen are up 21% in premarket trading, or $46.49, to $270.00.

  • 22

    Oct

BIIB Biogen
$223.57

3.52 (1.60%)

09/16/19
RBCM
09/16/19
NO CHANGE
RBCM
Biogen Phase II study of BG00011 discontinued due to toxicity, says RBC Capital
RBC Capital analyst Brian Abrahams noted that Biogen's Phase II study of BG00011, formerly STX-100, has been discontinued due to toxicity, and he confirmed this with the company. However, the analyst does not believe the discontinuation will impact shares or valuation, but added that "it does underscore some of the relatively high-risk nature of BIIB's pipeline and removes one of their potential internal diversification opportunities."
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
10/16/19
MSCO
10/16/19
NO CHANGE
Target $212
MSCO
Underweight
Biogen deadline to settle Tecfidera IPR challenge nearing, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that the USPTO's Patent Trial and Appeal Board will hold an oral hearing on November 13 for an IPR challenge of the only patent that protects Biogen's (BIIB) Tecfidera beyond 2020, after which he believes it will be hard for Biogen to settle out of this case. With that view in mind, he can see a scenario where Biogen reaches a settlement with both Mylan (MYL) and Sawai with a launch date before 2024, in which case he would foresee 1%-5% downside for Biogen shares. In a scenario where Biogen settles with launch date of 2024 or later, Harrison could see 5%-15% upside for Biogen shares. In a scenario where the oral hearing passes without a settlement, the analyst could see 1%-10% downside for Biogen shares. His base case expectation is that Biogen is unlikely to settle the IPR before the hearing, noted Harrison, who keeps an Underweight rating and $212 price target on Biogen shares.
10/16/19
BOFA
10/16/19
INITIATION
Target $200
BOFA
Underperform
Biogen reinstated with an Underperform at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Biogen with an Underperform rating and $200 price target, citing competitive risks for Spinraza in SMA, price/share erosion in MS, and a pipeline focused on high risk/reward assets.

TODAY'S FREE FLY STORIES

NXPI

NXP Semiconductors

$114.81

-1.13 (-0.97%)

, QCOM

Qualcomm

$87.43

-3.04 (-3.36%)

13:30
11/19/19
11/19
13:30
11/19/19
13:30
Hot Stocks
NXP Semiconductors down 1% as Qualcomm conducts analyst day meeting »

Qualcomm (QCOM) has been…

NXPI

NXP Semiconductors

$114.81

-1.13 (-0.97%)

QCOM

Qualcomm

$87.43

-3.04 (-3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

13:30
11/19/19
11/19
13:30
11/19/19
13:30
General news
Treasury Action: yields have continued to richen in cautious trading »

Treasury Action: yields…

BA

Boeing

$367.75

-1.75 (-0.47%)

13:26
11/19/19
11/19
13:26
11/19/19
13:26
Periodicals
Boeing says following NTSB recommendation, redesigning engine cover on 737 NG »

In an emailed statement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$8.35

0.77 (10.16%)

13:25
11/19/19
11/19
13:25
11/19/19
13:25
Options
ArQule call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/19/19
11/19
13:17
11/19/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/19/19
11/19
13:16
11/19/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUR

Murphy Oil

$23.43

-0.29 (-1.22%)

13:15
11/19/19
11/19
13:15
11/19/19
13:15
Options
Murphy Oil put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$182.47

4.45 (2.50%)

13:14
11/19/19
11/19
13:14
11/19/19
13:14
Hot Stocks
Abiomed says AHA analysis of Impella 'flawed' »

The Abiomed medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.46

-0.13 (-0.12%)

, LOW

Lowe's

$113.37

-1.66 (-1.44%)

13:14
11/19/19
11/19
13:14
11/19/19
13:14
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$110.46

-0.13 (-0.12%)

LOW

Lowe's

$113.37

-1.66 (-1.44%)

NTES

NetEase

$287.03

-3.07 (-1.06%)

CPRT

Copart

$86.50

0.49 (0.57%)

LB

L Brands

$17.21

-0.65 (-3.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 05

    Dec

  • 06

    Dec

URBN

Urban Outfitters

$29.13

-1.03 (-3.42%)

, ALC

Alcon

$58.96

0.07 (0.12%)

13:14
11/19/19
11/19
13:14
11/19/19
13:14
Earnings
Notable companies reporting after market close »

Notable companies…

URBN

Urban Outfitters

$29.13

-1.03 (-3.42%)

ALC

Alcon

$58.96

0.07 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 02

    Dec

  • 05

    Dec

GOOG

Alphabet

$1,318.29

-0.16 (-0.01%)

, GOOGL

Alphabet Class A

$1,316.50

-3.67 (-0.28%)

13:09
11/19/19
11/19
13:09
11/19/19
13:09
Hot Stocks
Google introduces Your News Update »

Google said in a blog…

GOOG

Alphabet

$1,318.29

-0.16 (-0.01%)

GOOGL

Alphabet Class A

$1,316.50

-3.67 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CANN

General Cannabis

$0.00

(0.00%)

13:06
11/19/19
11/19
13:06
11/19/19
13:06
Hot Stocks
General Cannabis to sell Greenhouse Office building for approx. $1.7M »

General Cannabis Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$31.90

0.38 (1.21%)

13:05
11/19/19
11/19
13:05
11/19/19
13:05
Options
MGM Resorts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMI

Cummins

$183.46

-0.13 (-0.07%)

, TSLA

Tesla

$358.76

8.77 (2.51%)

13:01
11/19/19
11/19
13:01
11/19/19
13:01
Hot Stocks
Electric truck firm Nikola to unveil 'game-changing' battery cell technology »

Nikola Motor, which…

CMI

Cummins

$183.46

-0.13 (-0.07%)

TSLA

Tesla

$358.76

8.77 (2.51%)

NAV

Navistar

$32.22

-0.3 (-0.92%)

GM

General Motors

$36.60

-0.02 (-0.05%)

PCAR

Paccar

$79.50

-0.48 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRSP

Crispr Therapeutics

$67.82

9.3 (15.89%)

12:57
11/19/19
11/19
12:57
11/19/19
12:57
Recommendations
Crispr Therapeutics analyst commentary  »

Crispr Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 07

    Dec

EPD

Enterprise Products

$25.24

-0.54 (-2.09%)

12:55
11/19/19
11/19
12:55
11/19/19
12:55
Options
Enterprise Products put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$47.25

-1.09 (-2.25%)

12:47
11/19/19
11/19
12:47
11/19/19
12:47
Recommendations
Altria Group analyst commentary  »

Altria slide on Juul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

MRK

Merck

$84.13

0.01 (0.01%)

12:44
11/19/19
11/19
12:44
11/19/19
12:44
Hot Stocks
Merck boosts quarterly dividend to 61c from 55c »

Merck announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 10

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

FNV

Franco-Nevada

$99.27

0.25 (0.25%)

12:40
11/19/19
11/19
12:40
11/19/19
12:40
Options
Put spread in Franco Nevada rolls position to higher delta »

Put spread in Franco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.47

0.09 (0.40%)

12:39
11/19/19
11/19
12:39
11/19/19
12:39
Hot Stocks
Independent Bank CFO Robert Shuster sells over $185K in company shares »

Independent Bank CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

NFLX

Netflix

$302.89

0.22 (0.07%)

, DIS

Disney

$148.62

0.97 (0.66%)

12:37
11/19/19
11/19
12:37
11/19/19
12:37
Periodicals
Survey finds Netflix cancelers blame price hikes, content for leaving, blog says »

Helen Back wrote in the…

NFLX

Netflix

$302.89

0.22 (0.07%)

DIS

Disney

$148.62

0.97 (0.66%)

AAPL

Apple

$266.45

-0.58 (-0.22%)

CMCSA

Comcast

$44.69

0.08 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 09

    Dec

  • 10

    Dec

AUPH

Aurinia Pharmaceuticals

$5.92

0.17 (2.96%)

12:25
11/19/19
11/19
12:25
11/19/19
12:25
Options
Aurinia Pharmaceuticals call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,318.96

0.51 (0.04%)

, GOOGL

Alphabet Class A

$1,318.08

-2.09 (-0.16%)

12:19
11/19/19
11/19
12:19
11/19/19
12:19
Periodicals
'Big Tech' firms 'defend' themselves in responses to regulators, Reuters says »

Alphabet's Google…

GOOG

Alphabet

$1,318.96

0.51 (0.04%)

GOOGL

Alphabet Class A

$1,318.08

-2.09 (-0.16%)

FB

Facebook

$199.25

1.8 (0.91%)

AMZN

Amazon.com

$1,753.39

0.69 (0.04%)

AAPL

Apple

$266.15

-0.88 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 26

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/19/19
11/19
12:17
11/19/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/19/19
11/19
12:16
11/19/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.